Background/Objectives: AlthoughHelicobacter pylori(H. pylori) eradication therapy is important for preventing gastric cancer (GC), the occurrence of GC afterH. pylorieradication remains a problem. In this study, the aim was to identify risk factors for GC afterH. pylorieradication by comparing long-term histological, endoscopic, and serological evaluations of patients with and without GC. Methods: Patients who underwentH. pylorieradication therapy at Oita University Hospital between June 1997 and August 2013 and were followed for at least 3 years with long-term endoscopy, histology, and serum biochemical tests were included, and the GC (215 cases) and non-GC (11 cases) groups were compared. Results: The GC group was older than the non-GC group at the time of eradication, had lower serum pepsinogen I/II levels, had severe endoscopic atrophic changes, had higher activity at the antrum, and inflammation and intestinal metaplasia (IM) at the corpus on updated Sydney system scoring. On long-term follow-up after eradication, the GC group had a wider range of endoscopic mucosal atrophy and a lower serum pepsinogen I/II ratio at any time point. Conclusions: Endoscopic mucosal atrophy and the serum pepsinogen I/II ratio are useful predictors of GC in patients postH. pylorieradication at any time point.
背景/目的：尽管幽门螺杆菌根除治疗对于预防胃癌至关重要，但根除后胃癌的发生仍是一个问题。本研究旨在通过比较胃癌患者与非胃癌患者的长期组织学、内镜及血清学评估结果，识别幽门螺杆菌根除后发生胃癌的风险因素。方法：纳入1997年6月至2013年8月期间在大分大学医院接受幽门螺杆菌根除治疗，并通过长期内镜、组织学及血清生化检测随访至少3年的患者，比较胃癌组（215例）与非胃癌组（11例）的临床特征。结果：胃癌组在根除治疗时年龄高于非胃癌组，血清胃蛋白酶原I/II水平较低，内镜下萎缩性改变更严重，根据更新后的悉尼系统评分，胃窦部活动性更高，胃体部炎症及肠上皮化生程度更显著。在根除后的长期随访中，胃癌组在任何时间点均表现出更广泛的内镜下黏膜萎缩及更低的血清胃蛋白酶原I/II比值。结论：内镜下黏膜萎缩程度和血清胃蛋白酶原I/II比值是幽门螺杆菌根除后患者在任何时间点发生胃癌的有效预测指标。
肿瘤(癌症)患者之家